Table 2

Clinical improvement as assessed by ACR criteria
Assessor (time point)
 Response
 ACZ885
 Placebo (n = 15)
 P value (10 mg/kg versus placebo)




0.3 mg/kg (n = 6)
 1.0 mg/kg (n = 6)
 3.0 mg/kg (n = 6)
 10 mg/kg (n = 19/20a)

Blinded observer (day 43)
 ACR20
 1 (17%)
 0 (0%)
 4 (67%)
 6 (32%)
 1 (7%)
 0.085

ACR50
 0 (0%)
 0 (0%)
 1 (17%)
 3 (16%)
 0 (0%)
 0.162

ACR70
 0 (0%)
 0 (0%)
 0 (0%)
 2 (11%)
 0 (0%)
 0.305
Investigator (any time within 6 weeks of treatment start)
 ACR20
 3 (50%)
 2 (33%)
 4 (67%)
 10 (50%)
 3 (20%)
 0.070

ACR50
 0 (0%)
 0 (0%)
 2 (33%)
 4 (20%)
 0 (0%)
 0.093

ACR70
 0 (0%)
 0 (0%)
 0 (0%)
 3 (15%)
 0 (0%)
 0.174

Shown are the number and percentage of patients achieving 20%, 50%, or 70% improvement in terms of American College of Rheumatology (ACR) criteria (ACR20, ACR50 and ACR70, respectively) at day 43 as assessed by a blinded observer and at any time point within 6 weeks of treatment start as assessed by the investigator. aNote that for one patient in the 10 mg/kg treatment group, the ACR criteria assessment by a blinded observer was not conducted at day 43.

Alten et al. Arthritis Research & Therapy 2008 10:R67   doi:10.1186/ar2438

Open Data